Work number - M 26 FILED

Presented I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY

Authors:
1. Mykhailo BUCHYNSKYI – PhD student of the Department of Microbiology, Immunology and Virology of I. Horbachevsky Ternopil National Medical University.

 

The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, has become a serious challenge for healthcare systems worldwide. The relationship between COVID-19 and metabolic-associated fatty liver disease (MAFLD), the presence of which increases the risk of severe COVID-19 and mortality, is particularly noteworthy. Chronic inflammation characteristic of MAFLD can contribute to the development of a cytokine storm during SARS-CoV-2 infection, which explains the increased risk of severe COVID-19 in such patients.

MAFLD can affect gene expression, which, in turn, can alter the course of COVID-19. Studies of AHR, FFAR, FXR, and TGR5 receptors, which play an important role in immune responses, bile acid metabolism, and other processes, can help to understand the mechanisms of interaction between MAFLD and COVID-19.

Genetic factors can also influence the severity of COVID-19. Studies have found that polymorphisms of genes associated with the immune response and other biological processes can increase the risk of developing severe forms of COVID-19. Polymorphisms of the IFNAR2, OAS1, OAS3, and ACE2 genes are particularly noteworthy.

Along with the study of comorbidities and genetic factors, the search for more effective ways to treat COVID-19 remains relevant. A promising direction is the development and use of antiviral drugs for oral administration, such as Nirmatrelvir/Ritonavir (Paxlovid), which has shown a significant reduction in the risk of hospitalization or death among patients with COVID-19. Despite the availability of vaccines and antiviral drugs, type I interferons (IFN) remain promising for the treatment of COVID-19. Studies have shown that IFNs may be effective against a variety of viruses, including coronaviruses.

The mechanisms by which Paxlovid affects the level of SpO₂, fibrinogen, and monocytes in patients with COVID-19 and MAFLD have been investigated. The effects of this drug on the clinical condition and laboratory parameters of patients with MAFLD, including the effect on liver function, have been studied.

The relationship between MAFLD and COVID-19 has been clarified. Additional studies have been conducted to clarify the causal relationship between MAFLD and the severity of COVID-19. The effect of MAFLD on the course of COVID-19 has been clarified and the factors that determine the increased risk of complications have been identified.

Studies of genetic factors that affect the severity of COVID-19 in patients with MAFLD, including single nucleotide polymorphisms of the IFNAR2, OAS1, OAS3, and ACE2 genes, have been expanded and their interaction has been investigated. Functional analysis of the identified genetic variants has been performed to clarify their role in the pathogenesis of COVID-19 and MAFLD.

The effect of MAFLD on the expression of AHR, FFAR2, FXR, and TGR5 genes on their role in the course of COVID-19 has been studied in detail. The role of these genes in the development of COVID-19 complications in pa

Number of publications: 7_ articles in journals included in category "A" (including _7_ in foreign publications), _3_ abstracts of reports. The total number of references to the authors' publications / h-index for the work according to databases is, respectively: Web of Science 45 / 4, Scopus 46 / _4_, Google Scholar 64 / _5_.

Name	Type	Size	File
Essay (Ukr.)	.pdf	2.69 MB	Download [2]
Information about the creative contribution	.pdf	285.49 KB	Download [3]
Citation review	.pdf	377.87 KB	Download [4]
Presentation of work	.pdf	2.46 MB	Download [5]